Stifel has reaffirmed its Buy rating on Regenxbio Inc. (NASDAQ:RGNX), setting a price target of $42.00 despite the stock's current price of $6.63, which reflects a 52% decline over the past six months. The firm hosted a discussion with Regenxbio's management about their gene therapy program, Sura-vec, which targets wet age-related macular degeneration and diabetic retinopathy. The company is approaching the readout of its significant ATMOSPHERE and ASCENT clinical trials, scheduled for the fourth quarter of 2026. However, Regenxbio is facing financial difficulties, reporting a first-quarter loss of $1.72 per share, which fell short of analyst expectations. Additionally, its revenue of $6.39 million was significantly below the anticipated $25.8 million. Despite these challenges, the stock experienced a brief uptick following positive results from a trial related to Duchenne muscular dystrophy. In contrast, Goldman Sachs has reduced its price target for the company to $10, citing regulatory uncertainties surrounding its RGX-202 filing planned for early 2027.